The Crohn’s Disease market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Crohn’s Disease pipeline products will significantly revolutionize the Crohn’s Disease market dynamics.

DelveInsight’s “Crohn’s Disease Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Crohn’s Disease, historical and forecasted epidemiology as well as the Crohn’s Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Crohn’s Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Crohn’s Disease Market Forecast

Some of the key facts of the Crohn’s Disease Market Report:

• The Crohn’s Disease market size was valued ~USD 10,777 million in 2024 and is anticipated to grow with a significant CAGR of 4.3% during the study period (2020-2034)

• In March 2025, Celltrion announced the U.S. launch of STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab), after receiving FDA approval in December 2024. STEQEYMA is authorized for the same indications as STELARA, ensuring reliable treatment options for both patients and healthcare providers.

• In March 2025, Johnson & Johnson announced that the FDA has approved TREMFYA® (guselkumab), making it the first and only IL-23 inhibitor offering both subcutaneous (SC) and intravenous (IV) induction options for adults with moderately to severely active Crohn’s disease (CD), a chronic inflammatory condition affecting the gastrointestinal tract.

• In February 2025, Eli Lilly shared findings from the VIVID-2 open-label extension study at the Crohn’s and Colitis Congress (CCC), revealing that most patients with moderately-to-severely active Crohn’s disease treated continuously with OMVOH for two years achieved sustained clinical and endoscopic outcomes, including 43.8% of patients who had previously failed biologic therapies.

• In January 2025, The FDA approved OMVOH (mirikizumab) for Crohn’s disease, reinforcing the role of IL-23 inhibitors. Demonstrating robust long-term effectiveness, OMVOH is also under investigation for use in pediatric patients, potentially fulfilling a critical unmet need in this group.

• In 2024, the Crohn’s disease market in the US held the largest share among the 7MM, reaching around USD 8,000 million, and it is projected to grow further at a CAGR of 4.5%.

• In 2024, Germany recorded the largest Crohn’s disease market size among European nations at approximately USD 670 million, while Spain had the smallest, with around USD 207 million.

• In 2024, Japan’s Crohn’s disease market size was estimated at around USD 423 million, representing about 4% of the overall 7MM market.

• In 2024, the United States reported approximately 1.1 million diagnosed prevalent cases of Crohn’s disease.

• In 2024, the United States accounted for the largest share of diagnosed prevalent Crohn’s disease cases, representing about 54% of the 7MM population, while EU4 and the UK made up roughly 42%, and Japan contributed around 4%.

• In 2024, Germany recorded the highest number of diagnosed Crohn’s disease cases among the EU4 countries, with 299,000 cases, followed by the UK with 234,000 cases, while Spain reported the fewest, at 93,000 cases.

• In 2024, the United States was estimated to have approximately 461,000 diagnosed prevalent cases of mild Crohn’s disease and around 755,000 cases classified as moderate-to-severe.

• Key Crohn’s Disease Companies: Merck, Eli Lilly and Company, RedHill Biopharma, Bristol Myers Squibb, Dr. Falk Pharma GmbH, Janssen-Cilag Ltd., AbbVie, EA Pharma Co., Ltd., Erasmus Medical Center, Takeda, Pfizer, Provention Bio, Inc., Mitsubishi Tanabe Pharma Corporation, and others

• Key Crohn’s Disease Therapies: OMVOH (mirikizumab/LY3074828), ENTYVIO (vedolizumab), Tulisokibart (MK-7240, PRA023), Mirikizumab, RHB-104, ZEPOSIA (ozanimod), budesonide, Guselkumab, Risankizumab SC, E6011, Infliximab, CDPATH™, Etrasimod, PRV-6527, MT-1303, and others

• In 2023, there were about 432,000 cases classified as mild, and approximately 708,000 cases classified as moderate to severe (including those that transitioned from mild to moderate to severe) in the United States.

• The Crohn’s Disease market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Crohn’s Disease pipeline products will significantly revolutionize the Crohn’s Disease market dynamics.

Crohn’s Disease Overview

Crohn’s Disease is a chronic inflammatory condition of the digestive tract that can affect any part from the mouth to the anus. It causes symptoms like abdominal pain, diarrhea, weight loss, and fatigue. The exact cause is unknown, but it involves an abnormal immune response, genetics, and environmental factors. Crohn’s Disease is a type of inflammatory bowel disease (IBD) that can lead to complications such as strictures, fistulas, and malnutrition. Treatment focuses on reducing inflammation, managing symptoms, and maintaining remission.

Get a Free sample for the Crohn’s Disease Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/crohns-disease-cd-market

Crohn’s Disease Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Crohn’s Disease Epidemiology Segmentation:

The Crohn’s Disease market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of Crohn’s Disease

• Prevalent Cases of Crohn’s Disease by severity

• Gender-specific Prevalence of Crohn’s Disease

• Diagnosed Cases of Episodic and Chronic Crohn’s Disease

Download the report to understand which factors are driving Crohn’s Disease epidemiology trends @ Crohn’s Disease Epidemiology Forecast

Crohn’s Disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Crohn’s Disease market or expected to get launched during the study period. The analysis covers Crohn’s Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Crohn’s Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Crohn’s Disease Therapies and Key Companies

• OMVOH (mirikizumab/LY3074828): Eli Lilly

• ENTYVIO (vedolizumab): Takeda Pharmaceutical

• Tulisokibart (MK-7240, PRA023): Merck

• AGMB-129: Agomab Therapeutics

• TREMFYA: Johnson & Johnson

• SKYRIZI + ABBV-382: Abbvie

• Mirikizumab: Eli Lilly and Company

• RHB-104: RedHill Biopharma

• ZEPOSIA (ozanimod): Bristol Myers Squibb

• budesonide: Dr. Falk Pharma GmbH

• Guselkumab: Janssen-Cilag Ltd.

• Risankizumab SC: AbbVie

• E6011: EA Pharma Co., Ltd.

• Infliximab: Erasmus Medical Center

• CDPATH™: Takeda

• Etrasimod: Pfizer

• PRV-6527: Provention Bio, Inc.

• MT-1303: Mitsubishi Tanabe Pharma Corporation

• E6011: EA Pharma

Discover more about therapies set to grab major Crohn’s Disease market share @ Crohn’s Disease Treatment Landscape

Crohn’s Disease Market Strengths

• Certain initiatives have been taken by private and government organizations to raise awareness about the disease.

• Newer, innovative treatments such as JAK inhibitors and immune modulators are being developed. Targeted therapies (mainly biologics) penetration rate in case of moderate to severe Crohn’s Disease patients is expected to be more in future owing to availability of more products with better clinical profile and patient convenient route of administration.

Crohn’s Disease Market Opportunities

• Drugs with similar efficacy but better safety profile and patient convenient route of administration are expected to have a significant impact on the Crohn’s Disease market dynamics.

• The Crohn’s Disease has complex pathophysiology, including genomes and immune responses, variable clinical manifestations and disease courses, stepwise treatment options, many clinical parameters for monitoring, and unpredictable complications

Scope of the Crohn’s Disease Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Crohn’s Disease Companies: Merck, Eli Lilly and Company, RedHill Biopharma, Bristol Myers Squibb, Dr. Falk Pharma GmbH, Janssen-Cilag Ltd., AbbVie, EA Pharma Co., Ltd., Erasmus Medical Center, Takeda, Pfizer, Provention Bio, Inc., Mitsubishi Tanabe Pharma Corporation, and others

• Key Crohn’s Disease Therapies: OMVOH (mirikizumab/LY3074828), ENTYVIO (vedolizumab), Tulisokibart (MK-7240, PRA023), Mirikizumab, RHB-104, ZEPOSIA (ozanimod), budesonide, Guselkumab, Risankizumab SC, E6011, Infliximab, CDPATH™, Etrasimod, PRV-6527, MT-1303, and others

• Crohn’s Disease Therapeutic Assessment: Crohn’s Disease current marketed and Crohn’s Disease emerging therapies

• Crohn’s Disease Market Dynamics: Crohn’s Disease market drivers and Crohn’s Disease market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Crohn’s Disease Unmet Needs, KOL’s views, Analyst’s views, Crohn’s Disease Market Access and Reimbursement

To know more about Crohn’s Disease companies working in the treatment market, visit @ Crohn’s Disease Clinical Trials and Therapeutic Assessment

Table of Contents

1. Crohn’s Disease Market Report Introduction

2. Executive Summary for Crohn’s Disease

3. SWOT analysis of Crohn’s Disease

4. Crohn’s Disease Patient Share (%) Overview at a Glance

5. Crohn’s Disease Market Overview at a Glance

6. Crohn’s Disease Disease Background and Overview

7. Crohn’s Disease Epidemiology and Patient Population

8. Country-Specific Patient Population of Crohn’s Disease

9. Crohn’s Disease Current Treatment and Medical Practices

10. Crohn’s Disease Unmet Needs

11. Crohn’s Disease Emerging Therapies

12. Crohn’s Disease Market Outlook

13. Country-Wise Crohn’s Disease Market Analysis (2020–2034)

14. Crohn’s Disease Market Access and Reimbursement of Therapies

15. Crohn’s Disease Market Drivers

16. Crohn’s Disease Market Barriers

17. Crohn’s Disease Appendix

18. Crohn’s Disease Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/